BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile

Author(s): F. Leonetti, A. Stefanachi, O. Nicolotti, M. Catto, L. Pisani, S. Cellamare, A. Carotti.

Journal Name: Current Medicinal Chemistry

Volume 18 , Issue 19 , 2011

Become EABM
Become Reviewer


Chronic myeloid leukemia (CML) is a myeloproliferative disease originating from a constitutively active tyrosine kinase, called BCR-ABL, expressed by an oncogene resulting from a reciprocal translocation between chromosome 9 and chromosome 22, coded as (t[9,22][q34;q11]). Inhibition of BCR-ABL with tyrosine kinase inhibitors (TKI) proved to be an efficient targeted therapy of Philadelphia-positive (Ph+) CML in the chronic phase. This review mainly addresses the synthetic pathways and process chemistry leading to the large scale preparation for pre-clinical demands and clinical supply of the three TKIs approved for Ph+ CML, i.e., imatinib, dasatinib and nilotinib and three more investigational drugs, i.e., bosutinib, ponatinib and bafetinib. Recent progress on the biochemical profiling of the six examined TKIs has been also reported.

Keywords: Chronic myeloid leukemia, BCR-ABL, tyrosine kinase inhibitors, T315I mutation, process chemistry

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [2943 - 2959]
Pages: 17
DOI: 10.2174/092986711796150414
Price: $58

Article Metrics

PDF: 13